- Home
- ACIU vs NUS Comparison
ACIU vs NUS Comparison
Compare ACIU & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- NUS
- Stock Information
- Founded
- ACIU 2003
- NUS 1984
- Country
- ACIU Switzerland
- NUS United States
- Employees
- ACIU N/A
- NUS N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- NUS Other Pharmaceuticals
- Sector
- ACIU Health Care
- NUS Health Care
- Exchange
- ACIU Nasdaq
- NUS Nasdaq
- Market Cap
- ACIU 332.4M
- NUS 377.3M
- IPO Year
- ACIU 2016
- NUS 1996
- Fundamental
- Price
- ACIU $2.68
- NUS $6.61
- Analyst Decision
- ACIU Strong Buy
- NUS Hold
- Analyst Count
- ACIU 2
- NUS 2
- Target Price
- ACIU $12.00
- NUS $8.88
- AVG Volume (30 Days)
- ACIU 134.5K
- NUS 799.5K
- Earning Date
- ACIU 11-05-2024
- NUS 02-12-2025
- Dividend Yield
- ACIU N/A
- NUS 3.64%
- EPS Growth
- ACIU N/A
- NUS N/A
- EPS
- ACIU N/A
- NUS N/A
- Revenue
- ACIU $48,505,404.00
- NUS $1,775,172,000.00
- Revenue This Year
- ACIU $85.33
- NUS N/A
- Revenue Next Year
- ACIU $80.69
- NUS $1.09
- P/E Ratio
- ACIU N/A
- NUS N/A
- Revenue Growth
- ACIU 4097200.00
- NUS N/A
- 52 Week Low
- ACIU $2.25
- NUS $5.95
- 52 Week High
- ACIU $5.14
- NUS $20.75
- Technical
- Relative Strength Index (RSI)
- ACIU 27.49
- NUS 36.34
- Support Level
- ACIU $2.62
- NUS $7.26
- Resistance Level
- ACIU $3.02
- NUS $7.51
- Average True Range (ATR)
- ACIU 0.13
- NUS 0.33
- MACD
- ACIU -0.05
- NUS -0.13
- Stochastic Oscillator
- ACIU 9.52
- NUS 2.94
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.